Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.72 |
| ▸ | MAP3K11 | Q16584 | 5/20 | 0.35 |
| ▸ | MTOR | P42345 | 5/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.32 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.31 |
| ▸ | AKT1 | P31749 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL978257 | 1.00 | CYP1A2 (0.72) | CYP1A2MAP3K11MTORSMN1; SMN2TLR9 | |
| Tirasemtiv SCHEMBL27969614 | 0.85 | CYP1A2 (1.00) | CYP1A2MTOR | |
| Tirasemtiv SCHEMBL976988 | 0.85 | CYP1A2 (1.00) | CYP1A2MTOR | |
| SCHEMBL977387 | 0.85 | CYP1A2 (0.49) | CYP1A2MAP3K11MTORSMN1; SMN2TLR9 | |
| SCHEMBL978018 | 0.85 | CYP1A2 (0.49) | CYP1A2MAP3K11MTORSMN1; SMN2TLR9 | |
| SCHEMBL977388 | 0.85 | CYP1A2 (0.49) | CYP1A2MAP3K11MTORSMN1; SMN2TLR9 | |
| SCHEMBL977806 | 0.81 | CYP1A2 (0.43) | CYP1A2MAP3K11SMN1; SMN2TLR9TLR7 | |
| SCHEMBL977316 | 0.78 | CYP1A2 (0.41) | CYP1A2 | |
| SCHEMBL13504133 | 0.78 | CYP1A2 (0.41) | CYP1A2 | |
| SCHEMBL978047 | 0.75 | CYP1A2 (0.40) | CYP1A2MAP3K11MTORSMN1; SMN2TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170266192-A1 | METHODS FOR IMPROVING DIAPHRAGM FUNCTION | CYTOKINETICS INC (US) | 2017-09-21 | — | — | US | claimed |
| EP-2069352-B9 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS INC (US) | 2017-03-15 | — | — | EP | claimed |
| EP-2995619-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS COMPRISING IMIDAZOPYRIMIDINES | Cytokinetics, Inc. (US) | 2016-03-16 | — | — | EP | claimed |
| EP-2583970-B1 | Certain chemical entities, compositions and methods comprising imidazopyrimidines | CYTOKINETICS INC (US) | 2015-10-14 | — | — | EP | claimed |
| US-20150065525-A1 | METHODS FOR IMPROVING DIAPHRAGM FUNCTION | CYTOKINETICS, INC. | 2015-03-05 | — | — | US | claimed |
| EP-2834269-A1 | METHODS FOR IMPROVING DIAPHRAGM FUNCTION | Cytokinetics, Inc. (US) | 2015-02-11 | — | — | EP | claimed |
| EP-2666777-A1 | Certain chemical entities having an imidazo<4,5-b>pyrazin-2(3H)-one core, compositions and methods | Cytokinetics, Inc. (US) | 2013-11-27 | — | — | EP | claimed |
| WO-2013151938-A1 | METHODS FOR IMPROVING DIAPHRAGM FUNCTION | CYTOKINETICS, INC. (US) | 2013-10-10 | — | — | WO | claimed |
| EP-2069352-B1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS INC (US) | 2013-10-09 | — | — | EP | claimed |
| EP-2583970-A1 | Certain chemical entities, compositions and methods comprising imidazopyrimidines | Cytokinetics, Inc. (US) | 2013-04-24 | — | — | EP | claimed |
| US-8299248-B2 | Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use | CYTOKINETICS, INCORPORATED (US) | 2012-10-30 | — | — | US | claimed |
| US-8293761-B2 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. (US) | 2012-10-23 | — | — | US | claimed |
| US-8227603-B2 | Modulating skeletal muscle | CYTOKINETICS, INC. (US) | 2012-07-24 | — | — | US | claimed |
| US-20110014212-A1 | Certain Chemical Entities, Compositions and Methods | CYTOKINETICS, INCORPORATED | 2011-01-20 | — | — | US | claimed |
| US-20100210645-A1 | Certain Chemical Entities, Compositions and Methods | CYTOKINETICS, INC. | 2010-08-19 | — | — | US | claimed |
| US-7598248-B2 | Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols, compositions thereof, and methods for their use | CYTOKINETICS, INC. (US) | 2009-10-06 | — | — | US | claimed |
| US-20080146561-A1 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. | 2008-06-19 | — | — | US | claimed |
| US-10766899-B2 | Methods for preparing substituted imidazo[4,5-b]pyrazines | CYTOKINETICS, INCORPORATED (US) | 2020-09-08 | — | — | US | disclosed |
| US-7598248-B2 | Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols, compositions thereof, and methods for their use | CYTOKINETICS, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-20080146561-A1 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210645-A1 | Certain Chemical Entities, Compositions and Methods | TNNC1, TNNI3, TNNT2 | CYP1A2 3794/4885MAP3K11 1398/4885MTOR 607/4885 |
| US-20170266192-A1 | METHODS FOR IMPROVING DIAPHRAGM FUNCTION | TNNC1, TNNI3, DIAPH1 | CYP1A2 4687/4885MAP3K11 3679/4885MTOR 4448/4885 |
| US-20150065525-A1 | METHODS FOR IMPROVING DIAPHRAGM FUNCTION | TNNC1, TNNI3, TNNT2 | CYP1A2 4502/4885MAP3K11 3980/4885MTOR 4845/4885 |
| US-20080146561-A1 | Certain chemical entities, compositions and methods | TNNC1, TNNI3, TNNT2 | CYP1A2 3794/4885MAP3K11 1398/4885MTOR 607/4885 |
| US-10766899-B2 | Methods for preparing substituted imidazo[4,5-b]pyrazines | CYP4B1, CYP3A5, CYP4F12 | CYP1A2 20/4885MAP3K11 1239/4885MTOR 3297/4885 |
| US-20110014212-A1 | Certain Chemical Entities, Compositions and Methods | TNNI3, TNNT2, TNNC1 | CYP1A2 3227/4885MAP3K11 1263/4885MTOR 2781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.